ImmunityBio Q3 product revenue up 434% YoY to $31.8M; net loss narrows to $67.3M

ImmunityBio, Inc.

2025-Q3 EPS reported -$0.32 revenue$75,003,000

Product revenue $31.8M in Q3 2025 vs $6.0M in Q3 2024; YTD sales $74.7M (+434%).
ANKTIVA unit volumes up 467% YTD 2025 vs FY2024; net loss attributable to common $67.3M (vs $85.7M).
Cash and securities $257.8M at Sep 30, 2025, up from $153.7M at Jun 30, 2025.
Early glioblastoma combo study: 100% disease control (2 near-complete responses, 3 stable).
Phase 3 NSCLC trial (ResQ201A) initiated; ANKTIVA named preferred drug by ~80M-life organization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.